FA
ADAP

FDx Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

FDx Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,445
Closed -$142K – 548
2018
Q3 		$142K Buy
+10,445
New +$109K 0.01% 856

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FDx Advisors's ADAP Position: Q4 2018 in Review

FDx Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2018, closing a stake of 10,445 shares — an estimated $142K sold.

FDx Advisors first reported a position in ADAP in Q3 2018 and held it in 1 quarter. The position peaked at $142K in Q3 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2018.

  • FDx Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • FDx Advisors sold 10,445 Adaptimmune Therapeutics shares in Q4 2018, an estimated $142K.
  • FDx Advisors first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 1 quarter.
  • FDx Advisors's Adaptimmune Therapeutics position peaked at $142K in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2018.

Based on FDx Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.